

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CD67DC2A3992EN.html>

Date: June 2022

Pages: 52

Price: US\$ 3,500.00 (Single User License)

ID: CD67DC2A3992EN

Abstracts

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Ophthalmology, Respiratory and Undisclosed which include indications Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Melanoma, Non-Hodgkin Lymphoma, Adenocarcinoma Of The Gastroesophageal Junction, Allergic Asthma, Allergic Conjunctivitis, Atopic Dermatitis (Atopic Eczema), Cervical Cancer, Chronic Urticaria Or Hives, Colon Tumor, Eosinophilic Esophagitis, Esophageal Cancer,

Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Liver Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Pancreatic Tumor, Rhinosinusitis, Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC) and Unspecified.

The latest report C-C Chemokine Receptor Type 4 – Drugs In Development, 2022, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 4

(K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects

The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Overview

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Companies Involved in

Therapeutics Development

ChemoCentryx Inc

CohBar Inc

Eight Plus One Pharmaceutical Co Ltd

Lassogen Inc

RAPT Therapeutics Inc

Tizona Therapeutics Inc

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Drug Profiles

BJY-809 – Drug Profile

Product Description

Mechanism Of Action

CB-5046 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CCX-6239 – Drug Profile

Product Description

Mechanism Of Action

History of Events

FLX-475 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas –
Drug Profile

Product Description

Mechanism Of Action

History of Events

LAS-20X – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Target CCR4 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

RPT-193 – Drug Profile

Product Description

Mechanism Of Action

History of Events

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Dormant Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Discontinued Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Product Development
Milestones

Featured News & Press Releases

May 23, 2022: RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in
Patients with Moderate-to-Severe Atopic Dermatitis

Mar 28, 2022: RAPT Therapeutics announces biomarker data from phase 1b trial of
RPT193 consistent with disease modification in atopic dermatitis

Oct 18, 2021: RAPT Therapeutics announces upcoming oral presentation of RPT193
phase 1b data at the 4th Inflammatory Skin Disease Summit

Sep 30, 2021: RAPT Therapeutics announces late-breaking oral presentation of positive
results from phase 1b trial of RPT193 at the 30th European Academy of Dermatology
and Venereology Congress

Sep 20, 2021: RAPT Therapeutics to present RPT193 phase 1b data at 30th European
Academy of Dermatology and Venereology Congress

Jun 14, 2021: RAPT Therapeutics reports positive topline results from phase 1b trial of
RPT193 monotherapy in atopic dermatitis

Jun 13, 2021: RAPT Therapeutics to report top line data from phase 1b trial of RPT193
in atopic dermatitis

Mar 22, 2021: Rapt Therapeutics completes enrollment in phase 1b trial of RPT193 in

atopic dermatitis

Nov 16, 2020: RAPT Therapeutics reports positive initial data from ongoing phase 1/2 clinical trial of FLX475 in multiple cancer indications

Nov 15, 2020: RAPT Therapeutics to announce initial data from phase 1/2 clinical trial of FLX475 in multiple cancer indications

May 15, 2020: RAPT Therapeutics highlights early results for RPT193 at Society for Investigative Dermatology Meeting

Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193

Jul 08, 2019: RAPT Therapeutics announces the appointment of Emma Guttman-Yassky, M.D., Ph.D., a leading expert in the field of inflammatory skin diseases, to its scientific advisory board

May 13, 2019: FLX Bio highlights preclinical atopic dermatitis and asthma data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019

Nov 29, 2018: ChemoCentryx announces presentation on novel small molecule inhibitor CCX6239 at American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by ChemoCentryx Inc, 2022

Pipeline by CohBar Inc, 2022

Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022

Pipeline by Lassogen Inc, 2022

Pipeline by RAPT Therapeutics Inc, 2022

Pipeline by Tizona Therapeutics Inc, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CD67DC2A3992EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD67DC2A3992EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970